SEC Form 4 · accession 0001628280-26-047217
TriSalus Life Sciences, Inc. · TLSI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Patience
Officer — Chief Financial Officer
Period of report
Jul 1, 2026
Accepted (ET)
Jul 6, 2026 · 4:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001826667
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 1, 2026 | F | 14,650 | $4.46 | D | 261,107 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units previously granted.